Drug Development/R&D

New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.

colourful short pencils next to each other
Insights

OHE’s submission to a parliamentary inquiry on UK drug shortages

6 October 2025

The following is an extract from OHE’s written submission to parliament focused on diversifying suppliers and recognising the value of treatment alternatives to mitigate this issue.

Insights

The Trump Administration’s US Drug Pricing Proposal – What will happen next?

12 June 2025

This is the second in our series of Insights considering the implications of President Trump’s Executive Order on ‘Most Favoured Nation’ drug pricing. We know that…

Insights

Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines

5 June 2025

Join us for an online CERSI-PGx Health Economics Workshop on 10 June 2025, from 13:00–17:00 BST, with experts from NHS England, NICE, the University of Manchester, and Bangor University.

Insights

GLP-1 Receptor Agonists: Shifting Obesity Management

12 May 2025

The glucagon-like peptide-1 (GLP-1) receptor agonist market is experiencing rapid growth, with more than 150 drug candidates currently in development as reported by Research & Markets,…

Publication

The Importance of Diversity of Supply in Rare Diseases Markets

23 January 2025

Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting treatment options. Our report explores how supplier diversity can enhance healthcare resilience and drive innovation, with actionable recommendations for policymakers.

Publication

A Spotlight on Haemophilia Therapies

3 October 2024

Pharmaceutical innovation is a key driver of improvements in health outcomes, quality of life and productivity for people with acute and chronic conditions.

Three rows of identical orange prescription bottles with white lids and labels, arranged neatly in a line, increasing in height from left to right against a white background.
Publication

The Cost of Drug Shortages

16 September 2024

Across the globe, drug shortages are becoming increasingly common.

A close-up image of a collection of orange prescription bottles neatly aligned in rows, with white caps and blank labels, against a white background. The repetitive pattern and bright color highlight the pharmaceutical industry’s mass production of medication.
Insights

Drug shortages are on the rise – but what is their impact?

16 September 2024

In this article, we discuss the global issue of drug shortages. We summarise our research where we developed a framework for quantifying the cost of a shortage, and through three case studies provide illustrative estimates of these costs.